Serum Transthyretin

Serum Transthyretin EDITORIAL Predictor of Amyloidosis Outcomes? See Article by Hanson et al Jose Nativi-Nicolau, MD The future depends on what you do today. ―Mahatma Gandhi biomarker is defined by the National Institutes of Health Biomarkers Def- initions Working Group as “a characteristic that is objectively measured A and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Several biomarkers have been studied in recent years; however, few are used in clinical practice. According to the US Preventive Services Task Force, the potential impact of a novel risk factor is based on the following: (1) its predictive ability, (2) its preva- lence in the target population, (3) the number of intermediate-risk individuals who are reclassified as high risk when the risk factor is applied, and (4) the net benefit (benefits minus harms) that would accrue to these high-risk individuals if they were managed according to guidelines for high-risk patients. Amyloidosis involves the transformation of a precursor protein into an insol- uble extracellular fibril that interferes with the function of the organs affected (Figure). The most common precursors include immunoglobulin light chains (AL amyloidosis), wild-type transthyretins (ATTRwt), and genetically mutated trans- thyretins (ATTRm). The field http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation: Heart Failure Wolters Kluwer Health

Serum Transthyretin

Loading next page...
 
/lp/wolters_kluwer/serum-transthyretin-6NNj00QGNy
Publisher
Wolters Kluwer
Copyright
© 2018 American Heart Association, Inc.
ISSN
1941-3289
eISSN
1941-3297
D.O.I.
10.1161/CIRCHEARTFAILURE.118.004802
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Predictor of Amyloidosis Outcomes? See Article by Hanson et al Jose Nativi-Nicolau, MD The future depends on what you do today. ―Mahatma Gandhi biomarker is defined by the National Institutes of Health Biomarkers Def- initions Working Group as “a characteristic that is objectively measured A and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Several biomarkers have been studied in recent years; however, few are used in clinical practice. According to the US Preventive Services Task Force, the potential impact of a novel risk factor is based on the following: (1) its predictive ability, (2) its preva- lence in the target population, (3) the number of intermediate-risk individuals who are reclassified as high risk when the risk factor is applied, and (4) the net benefit (benefits minus harms) that would accrue to these high-risk individuals if they were managed according to guidelines for high-risk patients. Amyloidosis involves the transformation of a precursor protein into an insol- uble extracellular fibril that interferes with the function of the organs affected (Figure). The most common precursors include immunoglobulin light chains (AL amyloidosis), wild-type transthyretins (ATTRwt), and genetically mutated trans- thyretins (ATTRm). The field

Journal

Circulation: Heart FailureWolters Kluwer Health

Published: Feb 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off